依列卡福妥-替扎卡福妥-依伐卡福妥对成年囊性纤维化患者脂质参数的影响：一项单中心初步报告。 - Suppr

Suppr

超能文献

Effect of elexacaftor-tezacaftor-ivacaftor on lipid parameters in adults with cystic fibrosis: A single centre preliminary report.

作者信息

Docherty Ronan, Folganan Jennifer, Dempsey Owen

机构信息

University of Aberdeen, School of Medicine, Medical Sciences and Nutrition, United Kingdom.

出版信息

Respir Med Res. 2024 Nov;86:101102. doi: 10.1016/j.resmer.2024.101102. Epub 2024 Mar 15.

DOI:10.1016/j.resmer.2024.101102

PMID:38852201

Abstract

摘要

相似文献

Effect of elexacaftor-tezacaftor-ivacaftor on lipid parameters in adults with cystic fibrosis: A single centre preliminary report.依列卡福妥-替扎卡福妥-依伐卡福妥对成年囊性纤维化患者脂质参数的影响：一项单中心初步报告。

Respir Med Res. 2024 Nov;86:101102. doi: 10.1016/j.resmer.2024.101102. Epub 2024 Mar 15.

Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis.依伐卡托与泰比卡托联合艾乐卡福特治疗对成年囊性纤维化患者体重和代谢参数的影响。

J Cyst Fibros. 2022 Mar;21(2):265-271. doi: 10.1016/j.jcf.2021.11.012. Epub 2021 Dec 1.

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对具有 II 类 CFTR 基因突变（最常见的是 F508del）的囊性纤维化患者的校正治疗（含或不含增效剂）。

Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.

Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化

N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。

Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.

Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.高效CFTR调节剂疗法对囊性纤维化患儿的实际影响。

Front Pharmacol. 2023 May 9;14:1176815. doi: 10.3389/fphar.2023.1176815. eCollection 2023.

The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.无 F508del CFTR 变异的囊性纤维化患者使用依伐卡托、泰它西普和埃拉卡托的法国扩大同情用药计划：一项真实世界研究。

Lancet Respir Med. 2024 Nov;12(11):888-900. doi: 10.1016/S2213-2600(24)00208-X. Epub 2024 Aug 13.

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验

Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.

Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.依伐卡托与泰他卡托和艾克巴司他联合制剂治疗囊性纤维化慢性鼻-鼻窦炎的疗效。

Am J Otolaryngol. 2024 May-Jun;45(3):104236. doi: 10.1016/j.amjoto.2024.104236. Epub 2024 Feb 24.

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.12岁及以上囊性纤维化患者使用万扎卡托-替扎卡托-地替瓦卡托与依列卡托-替扎卡托-艾伐卡托的对比研究（SKYLINE试验VX20 - 121 - 102和VX20 - 121 - 103）：两项随机、活性对照3期试验的结果

Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2.

引用本文的文献

Cystic Fibrosis Year in Review 2024.2024年囊性纤维化年度回顾

Pediatr Pulmonol. 2025 Aug;60(8):e71222. doi: 10.1002/ppul.71222.

New era, new GOALs: cardiovascular screening and lipid management in cystic fibrosis.新时代，新目标：囊性纤维化的心血管筛查与血脂管理

Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251317200. doi: 10.1177/17534666251317200.

Impact of Elexacaftor-Tezacaftor-Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study.依伐卡托与泰比卡托和艾氟康唑三联疗法对囊性纤维化患者体成分、饮食摄入、生物标志物和生活质量的影响：一项前瞻性观察研究。

Nutrients. 2024 Sep 28;16(19):3293. doi: 10.3390/nu16193293.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验